• Sanofi-Aventis


  • Symbion CP Holdings Pty Limited


The transaction concerned the acquisition of Symbion's consumer products business, which operated as Symbion CP Holdings Pty Limited (SC). SC mainly produced vitamins and dietary supplements known as nutraceuticals. The main area of overlap between SC and Sanofi-Aventis (SA) concerned the production of vitamin B1 products, as the only nutraceutical product SA manufactured was Betamin, a type of vitamin B1.

Market definition

The ACCC did not consider it necessary to reach a definitive view on the market definition in relation to this matter due to the lack of competition concerns likely to arise from the transaction. The ACCC considered however that there may be a market for the manufacture and supply of nutraceutical products.

Competition analysis

The ACCC considered that due to the minimal overlap between the parties and the existence of a number of competing nutraceutical producers in the market, including producers of vitamin B1 products, the transaction was unlikely to result in a substantial lessening of competition.


Date Event

ACCC commenced review under the Merger Review Process Guidelines.

Closing date for submissions from interested parties.

ACCC announced it would not oppose the proposed acquisition.